Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGEN NASDAQ:MRTX NASDAQ:NKTR NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ANKTRNektar Therapeutics$59.38+0.3%$74.59$7.99▼$109.00$2.01B1.13958,064 shs534,038 shsSAGESage Therapeutics$8.68$8.88$6.35▼$9.36$543.54M0.262.32 million shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%0.00%0.00%0.00%+26.47%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics0.00%+3.59%-20.11%-18.94%+521.78%SAGESage Therapeutics0.00%0.00%0.00%0.00%+28.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ANKTRNektar Therapeutics$59.38+0.3%$74.59$7.99▼$109.00$2.01B1.13958,064 shs534,038 shsSAGESage Therapeutics$8.68$8.88$6.35▼$9.36$543.54M0.262.32 million shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%0.00%0.00%0.00%+26.47%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics0.00%+3.59%-20.11%-18.94%+521.78%SAGESage Therapeutics0.00%0.00%0.00%0.00%+28.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGENFibroGen 2.00Hold$43.00340.12% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/ANKTRNektar Therapeutics 2.73Moderate Buy$149.63151.98% UpsideSAGESage Therapeutics 2.00Hold$9.377.91% UpsideCurrent Analyst Ratings BreakdownLatest SAGE, FGEN, MRTX, and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/11/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$95.00 ➝ $80.005/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.004/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026NKTRNektar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$151.00 ➝ $178.004/20/2026NKTRNektar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.003/24/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$70.003/17/2026NKTRNektar Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39NKTRNektar Therapeutics$55.23M36.33N/AN/A$4.41 per share13.46SAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ANKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%N/ALatest SAGE, FGEN, MRTX, and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFGENFibroGenN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGENFibroGenN/A3.713.60MRTXMirati TherapeuticsN/A7.547.40NKTRNektar TherapeuticsN/A10.2110.21SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGENFibroGen72.71%MRTXMirati TherapeuticsN/ANKTRNektar Therapeutics75.88%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipFGENFibroGen3.07%MRTXMirati Therapeutics3.26%NKTRNektar Therapeutics2.50%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGENFibroGen5704.05 million3.92 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionNo DataNKTRNektar Therapeutics22033.79 million32.94 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableFGEN, MRTX, NKTR, and SAGE HeadlinesRecent News About These CompaniesFormer Sage Therapeutics executives launch neurology biotech with $106MApril 21, 2026 | bizjournals.comTortugas comes out of shell with $106M, 4 ph. 2-stage neuro medsApril 21, 2026 | fiercebiotech.comFTortugas debuts with $106M and brain drugs from Hansoh, EisaiApril 21, 2026 | finance.yahoo.comBoston Man to Settle SEC Insider Trading Case Over Drug DenialJanuary 28, 2026 | news.bloomberglaw.comNSupernus a new buy at BofA on 'underappreciated' CNS assetsOctober 29, 2025 | seekingalpha.comBiogen’s Zurzuvae approved as first postpartum depression drug in EuropeSeptember 18, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMSage’s Search for Lifeline Ran Into Defiant Biogen CEOJuly 3, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, MRTX, NKTR, and SAGE Company DescriptionsFibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Nektar Therapeutics NASDAQ:NKTR$59.38 +0.17 (+0.29%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$59.96 +0.58 (+0.98%) As of 06/12/2026 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Sage Therapeutics NASDAQ:SAGESage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
